Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World

瑞戈非尼 医学 内科学 结直肠癌 不利影响 队列 队列研究 观察研究 肿瘤科 外科 癌症
作者
Qi Zhang,Mifen Chen,Zhenghang Wang,Changsong Qi,Yanshuo Cao,Junyan Zhang,Zhi Peng,Xicheng Wang,Ming Lu,Lin Shen,Jian Li
出处
期刊:Clinical Colorectal Cancer [Elsevier BV]
卷期号:21 (3): e152-e161 被引量:8
标识
DOI:10.1016/j.clcc.2022.01.007
摘要

BackgroundRegorafenib and fruquintinib are tyrosine kinase inhibitors that are recommended for refractory colorectal cancer (CRC) in China. However, to date, no head-to-head trials have been conducted to guide clinical practice.Methods and PatientsAn ambispective observational cohort study was conducted in Beijing Cancer Hospital. Patients with metastatic CRC who received regorafenib or fruquintinib were retrospectively collected between January 2018 and April 2020, and prospectively enrolled between May 2020 and February 2021. The primary outcome was time-to-treatment failure (TTF), and secondary outcomes were overall survival (OS) and adverse events. An additional goal of the study was to explore the appropriate sequence of regorafenib and fruquintinib treatment.ResultsA total of 366 patients with metastatic CRC were enrolled to receive regorafenib (n = 260) or fruquintinib (n = 106) between January 2018 and February 2021. No difference was observed for median TTF (regorafenib 2.7 months vs. fruquintinib 3.1 months, P = .200) or median OS (regorafenib 13.8 months vs. fruquintinib 11.3 months, P = .527). The propensity score analysis showed similar results for median TTF and median OS between the 2 groups, as did the results of subgroup analysis for prospective set (n = 146). For sequence analysis, patients with regorafenib followed by fruquintinib (n = 84) showed longer OS than that with the reverse (n = 29) (28.1 months vs. 18.4 months, P = .024). Most patients tolerated regorafenib at a reduced dose (93.1%), and most patients tolerated fruquintinib at a standard dose (68.9%). The incidences of most adverse events were similar between the two groups, while any grade of hand-foot skin reaction and hyperbilirubinemia were more frequently observed in the regorafenib group and ≥grade 3 hypertension was more common in the fruquintinib group.ConclusionRegorafenib and fruquintinib had similar efficacy and toxicity profiles with various frequency. Regorafenib followed by fruquintinib showed longer OS than the reverse, but the sequence needs to be further confirmed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
给我个二硫碘化钾完成签到,获得积分10
刚刚
刚刚
葛怀锐完成签到 ,获得积分10
刚刚
ada完成签到,获得积分10
1秒前
tian完成签到,获得积分10
1秒前
叶子完成签到,获得积分10
1秒前
1秒前
唐若冰完成签到,获得积分10
2秒前
frx1996完成签到,获得积分20
2秒前
小二郎应助front采纳,获得10
2秒前
伶俐妙海应助忐忑的远山采纳,获得40
2秒前
科研通AI2S应助zzs喵采纳,获得10
2秒前
2秒前
whitedawn完成签到 ,获得积分10
2秒前
隐形惜筠完成签到 ,获得积分10
3秒前
姜水完成签到,获得积分10
3秒前
叶子阳完成签到 ,获得积分10
3秒前
4秒前
4秒前
4秒前
权翼完成签到,获得积分10
4秒前
Orange应助郑昕玥采纳,获得10
4秒前
耍酷曼雁发布了新的文献求助30
5秒前
sj090完成签到,获得积分10
5秒前
5秒前
SYLH应助Loik采纳,获得10
5秒前
5秒前
wuta完成签到,获得积分10
6秒前
6秒前
6秒前
等你下课发布了新的文献求助10
6秒前
chen发布了新的文献求助10
6秒前
长风破浪发布了新的文献求助10
6秒前
6秒前
秋刀鱼完成签到,获得积分10
7秒前
7秒前
7秒前
7秒前
7秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968844
求助须知:如何正确求助?哪些是违规求助? 3513769
关于积分的说明 11169920
捐赠科研通 3249095
什么是DOI,文献DOI怎么找? 1794630
邀请新用户注册赠送积分活动 875278
科研通“疑难数据库(出版商)”最低求助积分说明 804755